-
-
-
-
-
-
-
Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
-
-
-
-
-
-
-
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation
-
-
-
-
-
-
-
Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones
-
-
-
-
-
-
-
Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase
-
-
-
-
-
-
-
Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing
-
-
-
-
-
-
-
Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board
-
-
-
-
-
-
-
Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial
-
1,231,056 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


